Clinical Significance of Immunoscore in Triple Negative Breast Cancer and Human Epidermal Growth Factor Receptor 2+ Breast Cancer

Main Article Content

Pride Zvikomborero Tshuma
Wang Wei Bo
Li Wen Huan

Abstract

Breast cancer is one of the leading causes of death among women in the world. Advancements have been made in respect to the diagnosis and management of breast cancer. In this review we are going to look at immunoscore as an additional method of predicting prognosis as well as treatment for patients with TNBC and HER2+ breast cancer. At the moment the Immunoscore strategy has advanced in colon cancer but for breast cancer the TNM classification is the only standardized method for grading as well as predicting prognosis in breast cancer patients. Metastasis and growth of breast tumors are largely influenced by the immune contexture. In invasive breast cancer, response to chemotherapy and prognosis are predicted by a higher immune cell count. Tumor infiltrating lymphocytes (TILs) are immune cells that have migrated to the tumor tissue and the local microenvironment. This population is indicative of an immune response generated by the patient against the malignancy. In TNBC and HER2+ disease in particular, the presence of TILs has been shown to correlate with a good prognosis and good response to chemotherapy. Thus, an implementation of immunoscore in breast cancer could be a good tool in terms prognosis as well as a predictive tool.

Keywords:
Immunoscore, tumor microenvironment, tumor infiltrating lymphocytes, breast cancer.

Article Details

How to Cite
Tshuma, P. Z., Bo, W. W., & Huan, L. W. (2021). Clinical Significance of Immunoscore in Triple Negative Breast Cancer and Human Epidermal Growth Factor Receptor 2+ Breast Cancer. Asian Oncology Research Journal, 4(1), 7-13. Retrieved from http://journalaorj.com/index.php/AORJ/article/view/30127
Section
Review Article

References

Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: A novel perspective. Cancer Res. 2007;67(5):1883-6.
DOI: 10.1158/0008-5472.CAN-06-4806
PMID: 17332313

Angell H, Galon J. From the immune contexture to the Immunoscore: The role of prognostic and predictive immune markers in cancer. Curr Opin Immunol. 2013; 25(2):261-7.
DOI: 10.1016/j.coi.2013.03.004

Epub 2013 Apr 8. PMID: 23579076

Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306.
DOI: 10.1038/nrc3245. PMID: 22419253

Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009; 27(35):5944-51.
DOI: 10.1200/JCO.2008.19.6147

Epub 2009 Oct 26. PMID: 19858404

Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity. 2013;39(1):11-26.
DOI: 10.1016/j.immuni.2013.07.008
PMID: 23890060.

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumors. J Pathol. 2014;232(2):199-209.
DOI: 10.1002/path.4287. PMID: 24122236
PMCID: PMC4255306.

Mlecnik B, Bindea G, Pagès F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011; 30(1):5-12.
DOI: 10.1007/s10555-011-9270-7
PMID: 21249426; PMCID: PMC3044219.

Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr Opin Immunol. 2010; 22(2):215-22.
DOI: 10.1016/j.coi.2010.02.006

Epub 2010 Mar 6.
PMID: 20207124.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: A worldwide task force. J Transl Med. 2012;10:205.
DOI: 10.1186/1479-5876-10-205
PMID: 23034130; PMCID: PMC3554496.

Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1.
DOI: 10.1186/1479-5876-10-1
PMID: 22214470; PMCID: PMC3269368.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-4.
DOI: 10.1126/science.1129139
PMID: 17008531.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610-8.
DOI: 10.1200/JCO.2010.30.5425

Epub 2011 Jan 18.
PMID: 21245428.

Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353(25):2654-66.
DOI: 10.1056/NEJMoa051424
PMID: 16371631.

Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, et al. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011;9:32.
DOI: 10.1186/1479-5876-9-32
PMID: 21439082; PMCID: PMC3078100.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011; 9:214.
DOI: 10.1186/1479-5876-9-214
PMID: 22168571; PMCID: PMC3338100.

Van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, et al. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med. 2011;3(108):108-44.
DOI: 10.1126/scitranslmed.3002785.
PMID: 22072636.

Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: Colon cancer and beyond. Clin Cancer Res. 2020; 26(2):332-339.
DOI: 10.1158/1078-0432.CCR-18-1851

Epub 2019 Aug 14
PMID: 31413009.

Pruneri G, Vingiani A, Denkert C. Tumor infiltrating lymphocytes in early breast cancer. Breast. 2018;37:207-214.
DOI: 10.1016/j.breast.2017.03.010

Epub 2017 Mar 28.
PMID: 28363679.

Tower H, Ruppert M, Britt K. The immune microenvironment of breast cancer progression. Cancers (Basel). 2019;11(9):1375.
DOI: 10.3390/cancers11091375
PMID: 31527531; PMCID: PMC6769749.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24(7):986-993.
DOI: 10.1038/s41591-018-0078-7

Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Dec;24(12):1941. PMID: 29942092.

Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med. 2005;2(9):e284.
DOI: 10.1371/journal.pmed.0020284

Epub 2005 Sep 6. PMID: 16124834; PMCID: PMC1198041.

Wieckiewicz J, Goto R, Wood KJ. T regulatory cells and the control of alloimmunity: From characterisation to clinical application. Curr Opin Immunol. 2010;22(5):662-8.
DOI: 10.1016/j.coi.2010.08.011

Epub 2010 Sep 23. PMID: 20869224; PMCID: PMC3025322.

Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: A gene-expression-based retrospective study. PLoS Med. 2016; 13(12):1002194.
DOI: 10.1371/journal.pmed.1002194
PMID: 27959923; PMCID: PMC5154505.

Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-70.
DOI: 10.1126/science.1203486
PMID: 21436444.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25.
DOI: 10.1016/j.coi.2014.01.004

Epub 2014 Feb 14. PMID: 24531241; PMCID: PMC4388310

O'Sullivan T, Saddawi-Konefka R, Vermi W, Koebel CM, Arthur C, White JM, et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med. 2012;209(10):1869-82.
DOI: 10.1084/jem.20112738

Epub 2012 Aug 27. PMID: 22927549; PMCID: PMC3457735.

Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol Rev. 2011;241(1):104-18.
DOI: 10.1111/j.1600-065X.2011.01007.x
PMID: 21488893; PMCID: PMC3727276.

Emens LA. Breast cancer immunobiology driving immunotherapy: Vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597-611.
DOI: 10.1586/era.12.147
PMID: 23253225; PMCID: PMC3587160.

Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158-65.
DOI: 10.1158/1078-0432.CCR-07-4756
PMID: 18698033.

Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103(3):264-72.
DOI: 10.1093/jnci/djq524

Epub 2010 Dec 29. PMID: 21191116.

Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
DOI: 10.1056/NEJMra0801289
PMID: 19228622.

Andre F, Berrada N, Desmedt C. Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol. 2010;22(6):547-51.
DOI: 10.1097/CCO.0b013e32833fb384
PMID: 20842030.

Denkert C, Loibl S, Noske A, Roller M, Müller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-13.
DOI: 10.1200/JCO.2009.23.7370

Epub 2009 Nov 16. Erratum in: J Clin Oncol. 2010 Feb 1;28(4):708. PMID: 19917869.

Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 200;354(8):809-20
DOI: 10.1056/NEJMoa053028
PMID: 16495393.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2014;25(8):1544-50.
DOI: 10.1093/annonc/mdu112

Epub 2014 Mar 7. PMID: 24608200.

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 20131;31(7):860-7.
DOI: 10.1200/JCO.2011.41.0902

Epub 2013 Jan 22. PMID: 23341518.

Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple- negative breast cancer: A retrospective multicenter study. Ann Oncol. 2014;25(3): 611-618.
DOI: 10.1093/annonc/mdt556

Epub 2014 Jan 8. Erratum in: Ann Oncol. 2015 Jul;26(7):1518. PMID: 24401929; PMCID: PMC3933248.

Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-60.
DOI: 10.1038/nrclinonc.2010.223
PMID: 21364688.